

IN THE CLAIMS:

Please amend claims 1, 2, 5-7, 12, 14-16, 18, 22, 26-27 and 30-34 as indicated below.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Amended) A composition for administration to animals including a combination of:
 - (a) at least one anti-inflammatory agent selected from the group comprising:
 - i) green-lipped mussel extract (GLME), or and/or a pharmacologically active green lipped mussel product, or both, and
 - ii) shark cartilage; with
 - (b) at least one enhancing agent selected from the group of:
 - i) a bark product or bark extract, exhibiting antioxidant properties, and
 - ii) shark cartilage;

and wherein for a composition including just one member from each group, the selected members must be different.

2. (Amended) A composition for administration to animals including a combination of:
 - (a) at least one anti-inflammatory agent selected from the group comprising:
 - i) green-lipped mussel extract (GLME), or and/or a pharmacologically active green lipped mussel product, or both, and
 - ii) shark cartilage, or pharmacologically active shark cartilage extract, or both;

with
 - (b) at least one enhancing agent selected from the group of:
 - i) a bark or plant product or bark or plant extract, exhibiting any one of antioxidant, anti-arthritis, and anti-inflammatory properties, and
 - ii) shark cartilage;

and wherein for a composition including just one member from each group, the selected members must be different.

3. (Previously Amended) The composition of claim 2, comprising either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of: shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.

4. (Previously Amended) The composition of claim 2, comprising an anti-inflammatory agent in combination with a chondroitin compound.

5. (Amended) The composition of claim 2, wherein said anti-inflammatory agent is either or both of shark cartilage and pharmacologically active shark cartilage extract in combination with any one or more of:

~~EnzogenolTM, PycnogenolTM~~; a bark extract equivalent of ~~EnzogenolTM or PycnogenolTM~~, chondroitin sulphate, and a chondroitin compound.

6. (Amended) The composition of claim 2, which includes, as an enhancing agent, ~~PycnogenolTM~~ a bark extract.

7. (Amended) The composition of claim 2, which includes one or more anti-oxidants other than ~~Enzogenol or equivalent~~ bark extracts.

8. (Previously Amended) The composition of claim 7, wherein said anti-oxidant is vitamin E.

9. (Previously Amended) The composition of claim 2, which includes deer velvet or a pharmacologically active extract thereof.

10. (Previously Amended) The composition of claim 2, which includes additional glycosaminoglycans other than those present in the selected anti-inflammatory or enhancing agents.

11. (Previously Amended) The composition of claim 2, comprising green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide gastro-intestinal protection against irritation by other components in the composition.

12. (Amended) The composition of claim 2, which also includes any one or more of the following components:

a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, ~~and compounds providing in a pharmacologically acceptable form one or more of the following elements:~~ manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, ~~and cobalt~~ and pharmaceutically acceptable forms thereof.

13. (Previously Amended) The composition of claim 2, which includes one or more pharmacologically active substances.

14. (Amended) The composition of claim 13, wherein said pharmacologically active substance is an anti-inflammatory other than green-lipped mussel extract (GLME), ~~and/or a pharmacologically active green-lipped mussel product,~~ both green-lipped mussel extract (GLME) and a pharmacologically active green-lipped mussel product, and shark cartilage.

15. (Amended) The composition of claim 2, formulated to be suitable for ~~addressing~~ treating any one or more of the following conditions in animals: inflammation, arthritis and chronic joint pain.

16. (Amended) The composition of claim 2, manufactured into a dosage form selected from the group consisting of a ~~bolus or tablet~~ bolus, a tablet, a capsule, a slow release implant, a liquid composition, a gel, a paste and combinations thereof.

17. (Previously Amended) The composition of claim 2, which is formulated for use with non-human mammals.

18. (Amended) The method for ~~addressing~~ treating joint problems in non-human animals consisting of the administration of composition of claim 2.

19. (Previously Amended) The method of claim 18, in which the method of administration is oral.

20-21. (Canceled)

22. (Amended) A method for treating a human suffering from one or more conditions selected from inflammation, degenerative joints ~~joint complaints~~, ~~other~~ cartiligenous degeneration, and gastrointestinal sensitivity or irritation, ~~and cancerous tumours~~, by administering a composition comprising two or more of

(i) a green-lipped mussel extract (GLME), ~~and/or~~ a pharmacologically active green lipped mussel product, or both;

(ii) shark cartilage, ~~and/or~~ pharmacologically active shark cartilage extract, or both; and

(iii) an antioxidant bark extract.

23. (Previously Presented) The composition of claim 7, which includes deer velvet or a pharmacologically active extract thereof.

24. (Previously Presented) The composition of claim 5, which includes additional glycosaminoglycans other than those present in the selected anti-inflammatory or enhancing agents.

25. (Previously Presented) The composition of claim 7, which includes additional glycosaminoglycans other than those present in the selected anti-inflammatory or enhancing agents.

26. (Amended) The composition of claim 5, which also includes any one or more of the following components:

a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, ~~and compounds providing in a pharmacologically acceptable form one or more of the following elements:~~ manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, ~~and cobalt~~ and pharmaceutically acceptable forms thereof.

27. (Amended) The composition of claim 10, which also includes any one or more of the following components:

a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, ~~and compounds providing in a pharmacologically acceptable form one or more of the following elements:~~ manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, ~~and cobalt~~ and pharmaceutically acceptable forms thereof.

28. (Previously Presented) The composition of claim 5, which includes one or more pharmacologically active substances.

29. (Previously Presented) The composition of claim 10, which includes one or more pharmacologically active substances.

30. (Amended) The composition of claim 5 wherein said pharmacologically active substance is an anti-inflammatory other than green-lipped mussel extract (GLME), ~~and/or~~ a pharmacologically active green-lipped mussel product, both green-lipped mussel extract (GLME) and a pharmacologically active green-lipped mussel product, and shark cartilage.

31. (Amended) The composition of claim 10, wherein said pharmacologically active substance is an anti-inflammatory other than green-lipped mussel extract (GLME), ~~and/or~~ a pharmacologically active green-lipped mussel product, both green-lipped mussel extract (GLME) and a pharmacologically active green-lipped mussel product, and shark cartilage.

32. (Amended) The composition of claim 5 formulated to be suitable for ~~addressing~~ treating any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.

33. (Amended) The composition of claim 10, formulated to be suitable for ~~addressing~~ treating any one or more of the following conditions in animals: inflammation, arthritis and chronic joint pain.

34. (Amended) The composition of claim 13, formulated to be suitable for ~~addressing~~ treating any one or more of the following conditions in animals: inflammation, arthritis and chronic joint pain.